Mylan N.V. is an American global generic and specialty pharmaceuticals company registered in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and global headquarters in Canonsburg, Pennsylvania, US. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients (APIs) for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan grew from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world.
Mylan went public on the OTC market in February 1973. It is listed on the NASDAQ, and its shares have been a component of NASDAQ Biotechnology, NASDAQ 100, and the S&P 500 indices.
The company develops and produces medicines for a wide range of medical disciplines, including oncology, anaphylaxis, antiretrovirals, cardiovascular, respiratory, dermatology, immunology, anaesthesia and pain management, infectious disease, gastroenterology, diabetology/endocrinology, and women’s healthcare.
In 2016, Mylan’s pricing of the EpiPen, an epinephrine autoinjector, became controversial and was widely referred to as “price gouging”. As a result, investigations were opened into whether Mylan had misclassified the EpiPen under the Medicaid Drug Rebate Program, a common form of pharmaceutical fraud. In October 2016, Mylan settled these investigations with the U.S. Department of Justice, agreeing to pay $465 million and enter into a corporate integrity agreement concerning the rebate program. In a report published on June 12, 2017, Institutional Shareholder Services criticized Mylan for the “outsized compensation” of Mylan’s directors. Former CEO Robert Coury received a $98 million 2016 pay package in spite of shareholder losses and the perceived harm to the company inflicted by the EpiPen controversies. The report urged Mylan’s shareholders to oust all of Mylan’s existing directors.
Vincent Verschraegen, country manager of Mylan Belgium and Luxembourg, speaks about his onboarding in the company and what attracted him to join the organization. Verschraegen also discusses Mylan’s evolution from…
Milan Černek, country manager of Mylan in the Czech Republic, provides expert insights into current trends in the Czech Republic’s generics and biosimilars markets, describes the affiliate’s strategy to continue…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Funda Gücer, country manager at Mylan Turkey, portrays her experience in introducing the company to the Turkish market. She provides her expert insights into current trends in the Turkish generics…
Experienced country manager, João Madeira, introduces Mylan’s new vision to be a global healthcare company serving patients across the world with their hybrid generic, OTC and innovative pharmaceutical business model…
After a series of recent acquisitions, developing a diverse portfolio comprising four business areas; including OTC and branded prescription medicines, Mylan UK’s country manager, Jean-Yves Brault, takes a step back…
Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to…
Janis Kalejs, country manager Baltics at Mylan, discloses the strategies he has used to successfully lead his affiliate through corporate changes and explains how Mylan aims to continue providing affordable…
Milos Davidovic, Mylan’s country manager responsible for Serbia, Slovenia, Macedonia, and Montenegro, reveals the made-to-measure market approach that he has been implementing in the region for the past six years…
Yavor Kostov, country manager at Mylan in Bulgaria, discloses his strategies to successfully lead an affiliate through corporate changes and explains the important mission of Mylan to provide high-quality treatments…
Mylan Hungary’s Tamas Uri discusses transitioning into both a branded and generic business dedicated company, Mylan’s expansion in Hungary, and how the pharmaceutical industry can be a key player in improving the…
The general manager of one of the world’s largest API manufacturers recalls the recent acquisition of Abbott by Mylan and the processes which he has undertaken to set his entity…
Javier Anitua, Managing Director of Mylan Spain, discusses the preservation of Spain’s pharmacy model, preventive solutions for pharmacists, and the need for higher generic penetration in Spain. What more…
Poland has an important manufacturing role for the CEE region and this is where Mylan has settled Agila, a state-of-the-art, high quality injectables manufacturing platform. Mylan has great ambitions in…
João Madeira, General Manager of Mylan Portugal provides an overview of the state of generics in Portugal today, discussing structural issues related to Portugal’s low generic medicines penetration, ways to…
Mylan embarked upon its first major international expansion program in 2007, after the acquisition of Merck KGaA’s generic medicines business. How has the organization subsequently evolved in the UK/Ireland market…
The generics market in Belgium doesn’t seem to be at the level it deserves to be. Considering that Mylan controls about 14% of the local generics market share, how would…
Mr. Miller, you have been Vice President and Managing Director of Mylan’s operations in South Africa since 2008. What mission were you assigned back then, and in those three years,…
The Head of Viatris Latin America, Patrick Doyle, spoke to PharmaBoardroom about setting up the two-year old company’s Latam affiliate during the pandemic, the decision to focus on specific therapeutic…
Okan Güner of Viatris Turkey introduces the company’s sizeable footprint in the country, including local manufacturing and explains the challenges of executing an integration of two companies during the COVID-19…
In November 2020, after months of delay caused by COVID-19 disruptions and a US antitrust roadblock, Mylan and Pfizer’s Upjohn generics unit finally closed a USD 12 billion merger. The…
Squirreled away in the lowlands of North West Europe and somewhat dwarfed by the mighty neighbouring pharmaceutical powerhouses of Germany and France, one could easily be forgiven for overlooking Belgium’s…
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European…
Vincent Verschraegen, country manager of Mylan Belgium and Luxembourg, speaks about his onboarding in the company and what attracted him to join the organization. Verschraegen also discusses Mylan’s evolution from…
Multinational pharmaceutical companies are increasingly seeing Morocco as a top manufacturing destination for the African continent. Firms from Europe, Asia-Pacific and the US are investing millions of dollars in bolstering…
Milan Černek, country manager of Mylan in the Czech Republic, provides expert insights into current trends in the Czech Republic’s generics and biosimilars markets, describes the affiliate’s strategy to continue…
Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia…
Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in…
Funda Gücer, country manager at Mylan Turkey, portrays her experience in introducing the company to the Turkish market. She provides her expert insights into current trends in the Turkish generics…
2018 has been an exciting year in world health and our team has spanned the globe to bring you in-depth country reports and high profile interviews with leaders from the…
See our Cookie Privacy Policy Here
